[ { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#Head", "@graph": [ { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#pubinfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] }, { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#assertion", "@graph": [ { "@id": "http://purl.obolibrary.org/obo/DOID_3393", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association", "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [ { "@id": "http://purl.obolibrary.org/obo/DOID_3393" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [ { "@id": "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [ { "@id": "https://identifiers.org/drugbank:DB00315" } ], "@type": [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "\"Zolmitriptan is contraindicated in patients with: Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or c Warnings and Precautions ( 5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions ( 5.4 Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 Ischemic bowel disease [see Warnings and Precautions ( 5.5 Uncontrolled hypertension [see Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that is within 2 weeks) [see Drug Interactions ( 7.2 Clinical Pharmacology ( 12.3 Known hypersensitivity to zolmitriptan (angioedema and anaphylaxis seen) [see Adverse Reactions ( 6.2 History of coronary artery disease (CAD) or coronary vasospasm ( 4 Symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 Monamine oxidase (MAO)-A inhibitor used in past 2 weeks ( 4 Known hypersensitivity to zolmitriptan ( 4\"" } ], "https://w3id.org/biolink/vocab/provided_by": [ { "@id": "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation": [ { "@id": "https://schema.org/MedicalContraindication" } ] }, { "@id": "https://identifiers.org/drugbank:DB00315", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Drug" } ] } ] }, { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#provenance", "@graph": [ { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#assertion", "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ] } ] }, { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#pubinfo", "@graph": [ { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "UFwMfnbaGsXMkKmJYORpF/4E3FM7g3KhP0yfjN0fKHKIV9GFuTXvLVRHgYEH1Yq0OYpIpgZjfYj0FkXU00esIvAETt0rGwEMQSbF10Tyn3wib73rmbaBBgmsn+KRJ3f6WReLN/Npt7VCmSII64VkrwrF7SUIXvHATMHo0rR4AlU=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs" } ] }, { "@id": "http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs", "http://purl.org/dc/terms/created": [ { "@value": "2021-08-23T18:00:23.548+02:00", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://purl.org/dc/terms/creator": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [ { "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [ { "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] } ] } ]